UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

SCHEDULE 13G

(Amendment No. 3)*

Under the Securities Exchange Act of 1934

Kala Pharmaceuticals Inc.
(Name of Issuer)
Common Stock, Par Value \$0.001 Per Share
·
(Title of Class of Securities)
483119103
(CUSIP Number)
7. 1. 24.2022
December 31, 2020
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o Rule 13d-1(b)

☑ Rule 13d-1(c)

o Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 483119103	SCHEDULE 13G	Page 2 of 8 Pages
---------------------	--------------	-------------------

	1				
NAME OF REPORTING PERSONS					
1	OrbiMed Capital GP VI LLC				
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) 0				
	(a) 0 (b) o				
	SEC USE ONLY				
3					
4	CITIZENSHIP (OR PLAC	CE OF ORGANIZATION		
4	Delaware				
		5	SOLE VOTING POWER		
	NUMBER OF				
NU			0		
_	HARES	6	SHARED VOTING POWER		
	BENEFICIALLY OWNED BY		4,461,781		
	EACH		SOLE DISPOSITIVE POWER		
	PORTING ERSON	7			
	WITH		0		
	g	8	SHARED DISPOSITIVE POWER		
		"	4,461,781		
	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
9	4,461,781				
-		ACCDE	CATE AMOUNT IN DOW (A) EVOLUDES CERTAIN SHARES		
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0				
10					
	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
11	7.96%				
	TYPE OF REPORTING PERSON				
12					
	00				

CUSIP No. 483119103	SCHEDULE 13G	Page 3 of 8 Pages
---------------------	--------------	-------------------

	r				
1	NAME OF REPORTING PERSONS				
1	OrbiMed Advisors LLC				
	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP				
2	(a) 0				
	(b) o				
	SEC USE ONLY				
3					
	CITIZENSHIP OR PLACE OF ORGANIZATION				
4	CITIZEIVSIIII	JK I L/IC	E OF OROTHIZATION		
	Delaware				
			SOLE VOTING POWER		
		5	0		
	NUMBER OF SHARES		SHARED VOTING POWER		
_	EFICIALLY	6			
	VNED BY		4,714,195		
	EACH PORTING	7	SOLE DISPOSITIVE POWER		
P	PERSON	RSON '	0		
	WITH		SHARED DISPOSITIVE POWER		
		8	4.74.405		
	T		4,714,195		
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9			T BENEFICIALLY OWNED BY EACH REPORTING PERSON		
3	4,714,195				
	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0				
10					
—	DED CENTE OF C	רו אככ ח	EDDESENTED DV AMOUNIT IN DOW (0)		
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
	8.41%				
4.5	TYPE OF REPORTING PERSON				
12	IA				

CUSIP No. 483119103	SCHEDULE 13G	Page 3 of 8 Pages
---------------------	--------------	-------------------

	T				
1	NAME OF REPORTING PERSONS				
1	OrbiMed Capital LLC				
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o				
	(b) o				
	SEC USE ONLY				
3					
<u> </u>					
4	CITIZENSHIP	JR PLAC	CE OF ORGANIZATION		
	Delaware	Delaware			
			SOLE VOTING POWER		
		5	750.005		
NU	NUMBER OF SHARES		750,835		
			SHARED VOTING POWER		
	EFICIALLY VNED BY	6	0		
	EACH		SOLE DISPOSITIVE POWER		
	PORTING PERSON	7	750,835		
	WITH				
		8	SHARED DISPOSITIVE POWER		
			0		
	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
9	750,835				
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0				
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
11	1.34%				
	TYPE OF REPORTING PERSON				
12					
IA					

EXPLANATORY NOTE

This Amendment No. 3 to Schedule 13G is being filed to correct an error in the number of securities and the percentage of the outstanding shares of common stock, par value \$0.001 per share, of Kala Pharmaceuticals, Inc., beneficially owned by the reporting persons as of December 31, 2020, and that were reported in Amendment No. 2 to Schedule 13G, filed with the Securities and Exchange Commission on February 12, 2021.

Item 1. (a) Name of Issuer:

Kala Pharmaceuticals, Inc.

(b) Address of Issuer's Principal Executive Offices:

100 Beaver Street, Suite 201

Waltham, MA 02453

Item 2. (a) Name of Person Filing:

OrbiMed Capital GP VI LLC

OrbiMed Advisors LLC

OrbiMed Capital LLC

(b) Address of Principal Business Office:

601 Lexington Avenue, 54th Floor

New York, NY 10022

(c) Citizenship:

Please refer to Item 4 on each cover page for each Reporting Person.

(d) Title of Class of Securities:

Common Stock, Par Value \$0.001 Per Share

(e) CUSIP No.:

483119103

Item 3.

OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OrbiMed Private Investments VI, LP. OrbiMed Advisors LLC ("Advisors") and OrbiMed Capital LLC ("Capital") are investment advisors in accordance with ss.240.13d-1(b)(1)(ii)(E) and Advisors is the managing member of GP VI.

Item 4. Ownership:

Information with respect to the Reporting Person's ownership as of December 31, 2020 is incorporated by reference to items (5) - (9) and (11) of the cover page for the Reporting Person.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [].

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

The reporting persons are holding 9.75% of the shares in the aggregate on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities. Advisors exercises investment and voting power over the shares through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Common Stock reported herein.

Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

Not Applicable.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: March 1, 2021

OrbiMed Advisors LLC

By: /s/ Jonathan T. Silverstein

Name: Jonathan T. Silverstein

Title: Member

OrbiMed Capital GP VI LLC

By: OrbiMed Advisors LLC, its Managing Member

By: /s/ Jonathan T. Silverstein

Name: Jonathan T. Silverstein

Title: Member of OrbiMed Advisors LLC

OrbiMed Capital LLC

By: /s/ Jonathan T. Silverstein

Name: Jonathan T. Silverstein

Title: Member

EXHIBIT A JOINT FILING AGREEMENT

The undersigned hereby agree that the Statement on this Schedule 13G dated February 12, 2021 (the "Schedule 13G"), with respect to the Common Stock, par value \$0.001 per share, of Kala Pharmaceuticals, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of March 1, 2021.

OrbiMed Advisors LLC

By: /s/ Jonathan T. Silverstein

Name: Jonathan T. Silverstein

Title: Member

By: /s/ Sven H. Borho

Name: Sven H. Borho Title: Member

By: /s/ Carl L. Gordon

Name: Carl L. Gordon Title: Member

OrbiMed Capital GP VI LLC

By: OrbiMed Advisors LLC, Its Managing Member

By: /s/ Jonathan T. Silverstein

Name: Jonathan T. Silverstein

Title: Member of OrbiMed Advisors LLC

By: /s/ Sven H. Borho

Name: Sven H. Borho

Title: Member of OrbiMed Advisors LLC

By: /s/ Carl L. Gordon

Name: Carl L. Gordon

Title: Member of OrbiMed Advisors LLC

OrbiMed Capital LLC

By: /s/ Jonathan T. Silverstein

Name:Jonathan T. Silverstein

Title: Member

By: /s/ Sven H. Borho

Name:Sven H. Borho Title: Member

By: /s/ Carl L. Gordon

Name:Carl L. Gordon Title: Member